IN8bio, Inc. (INAB) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 5.27M | 4.94M | 3.85M | 5.09M | 5.55M | 6.16M | 7.09M | 8.63M | 8.56M | 7.93M | 7.17M | 7.71M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.65M | 2.38M | 1.86M | 2.71M | 2.69M | 2.63M | 2.73M | 3.53M | 3.74M | 3.08M | 3.38M | 3.58M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.61M | 2.65M | 2.1M | 2.49M | 2.97M | 3.59M | 3.31M | 5.16M | 4.9M | 4.52M | 3.79M | 4.13M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -91K | -113K | -107K | -110K | -64K | 1000K | -60K | -83K | 330K | 0 | 0 |
| Operating Income | -5.09M | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M | -7.93M | -7.17M | -7.71M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 8.29% | 19.77% | 45.61% | 40.97% | 35.18% | 22.3% | 1.16% | -11.85% | -13.78% | -1.67% | 3.11% | -7.47% |
| EBITDA | -5.09M | -4.42M | -3.33M | -4.31M | -4.88M | -5.46M | -6.4M | -8M | -7.93M | -7.3M | -6.52M | -7.08M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -4.28% | 19% | 47.98% | 46.11% | 38.45% | 25.24% | 1.93% | -13% | -14.35% | 1.96% | 8.82% | -2.51% |
| D&A (Non-Cash Add-back) | 0 | 521K | 527K | 784K | 669K | 702K | 690K | 631K | 632K | 627K | 647K | 637K |
| EBIT | 0 | -5.03M | -3.85M | -5.2M | -5.66M | -6.22M | -6.04M | -8.69M | -8.64M | -7.93M | -7.17M | -7.71M |
| Net Interest Income | 0 | 91K | 113K | 107K | 110K | 64K | 23K | 60K | 83K | 0 | 0 | 0 |
| Interest Income | 176K | 91K | 113K | 107K | 110K | 64K | 23K | 60K | 83K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 330K | 0 | 0 |
| Pretax Income | -5.09M | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M | -7.6M | -7.17M | -7.71M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.09M | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M | -7.6M | -7.17M | -7.71M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 8.29% | 19.77% | 45.61% | 40.97% | 35.18% | 18.93% | 1.16% | -11.85% | -13.78% | 2.56% | 3.11% | -7.47% |
| Net Income (Continuing) | -5.09M | -4.94M | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M | -8.63M | -8.56M | -7.6M | -7.17M | -7.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26 | -0.51 | -0.85 | -1.24 | -0.07 | -0.09 | -0.15 | -0.19 | -0.20 | -0.21 | -0.23 | -0.27 |
| EPS Growth % | -290.98% | -500% | -466.67% | -552.63% | 66.75% | 59.52% | 34.78% | 29.63% | 33.33% | 34.38% | 32.35% | 28.95% |
| EPS (Basic) | -0.26 | -0.51 | -0.85 | -1.24 | -0.07 | -0.09 | -0.15 | -0.19 | -0.20 | -0.21 | -0.23 | -0.27 |
| Diluted Shares Outstanding | 19.47M | 4.37M | 4.54M | 4.12M | 83.48M | 56.67M | 47.32M | 45.13M | 43.29M | 35.8M | 31.55M | 28.47M |
| Basic Shares Outstanding | 19.47M | 4.37M | 4.54M | 4.12M | 83.48M | 56.67M | 47.32M | 45.13M | 43.29M | 35.8M | 31.55M | 28.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |